Pde1 as a target therapeutic in heart disease
AssigneeUniversity of Utah Research Foundation
InventorMatthew Movsesian
Life of this patent
Estimating the term…
Abstract
Disclosed are compositions and methods related to inhibition of PDE1.
Claims35
A method of inhibiting cyclic nucleotide phosphodiesterase 1 (‘PDE1’) in any part of the heart muscle of a subject, the method comprising:
- a) identifying a subject who may benefit from PDE1 inhibition;
- and
- b) administering to the subject an inhibitor of PDE1.
6-15. (canceled)
A method of increasing cGMP, cAMP, or cGMP and cAMP content or concentration in any part of the heart muscle of a subject, the method comprising:
- a) identifying a subject in need thereof;
- and
- b) administering to the subject an inhibitor of PDE1, thereby increasing cGMP, cAMP, or cGMP and cAMP content or concentration.
22-23. (canceled)
28-37. (canceled)
A method of treating a subject with heart disease, the method comprising:
- a) screening for a test compound that inhibits catalytic activity of PDE1, by
- i) contacting PDE1 with a test compound;
- and
- ii) detecting interaction between PDE1 the test compound;
- iii) determining if the test compound inhibits PDE1;
- and
- iv) if the results of step iii are positive, selecting the test compound that inhibits PDE1;
- b) administering the test compound selected in step iv to a subject in need thereof, thereby treating a subject with heart disease.
A method of screening for a compound that increases cGMP concentration in any part of the heart muscle by inhibiting PDE1, the method comprising:
- a) contacting PDE1 with a test compound;
- b) determining the concentration of cGMP in the presence of the test compound and PDE1;
- wherein increased concentration of cGMP in the presence of the test compound and PDE1 (relative to cGMP concentration in the absence of the test compound) indicates the test compound increases cGMP concentration.
A method of screening for a compound that increases cAMP concentration in any part of the heart muscle by inhibiting PDE1, the method comprising:
- a) contacting PDE1 with a test compound;
- b) determining the concentration of cAMP in the presence of the test compound and PDE1;
- wherein increased concentration of cAMP in the presence of the test compound and PDE1 indicates the test compound increases cAMP concentration
A method of screening for a compound that increases cGMP and cAMP concentration in any part of the heart muscle by inhibiting PDE1, the method comprising:
- a) contacting PDE1 with a test compound;
- b) determining the concentration of cGMP and cAMP in the presence of the test compound and PDE1;
- wherein increased concentration of cGMP and cAMP in the presence of the test compound and PDE1 indicates the test compound increases cGMP and cAMP concentration.
A method of identifying a test compound that modulates interaction of PDE1 with one or more further molecules, the method comprising:
- a) contacting PDE1 with a test compound in the presence of one or more further molecules;
- and
- b) determining interaction of PDE1 with one or more further molecules in the presence of the test compound, as compared to a control;
- thereby identifying a test compound that modulates interaction of PDE1 with one or more further molecules.
Dependencies are inferred from the claim text.